The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | A multi-center observational study comparing BR to RCD in Waldenström’s macroglobulinemia
Francesco Autore, MD, PhD, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, discusses a multi-center study comparing bendamustine and rituximab (BR) to rituximab, cyclophosphamide and dexamethasone (RCD) in Waldenström’s macroglobulinemia. The study found that the BR group had better progression-free survival (PFS) and response rates. The tolerability was comparable, although those treated with BR had higher hematological toxicity. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
